loading page

Effective Use of ALK Inhibitors in EML4::ALK Positive Lymphatic Malformations
  • +5
  • Beth Apsel Winger,
  • Christopher F. Dowd,
  • Kristin Shimano,
  • Walter Patrick Devine,
  • Erin Mathes,
  • Ilona Friedan,
  • Carrie Schaefer,
  • Alok Kothari
Beth Apsel Winger
University of California San Francisco Department of Clinical Pharmacy

Corresponding Author:[email protected]

Author Profile
Christopher F. Dowd
University of California San Francisco Department of Radiology and Biomedical Imagery
Author Profile
Kristin Shimano
University of California San Francisco Department of Pediatrics
Author Profile
Walter Patrick Devine
University of California San Francisco
Author Profile
Erin Mathes
University of California San Francisco Department of Dermatology
Author Profile
Ilona Friedan
University of California San Francisco Department of Dermatology
Author Profile
Carrie Schaefer
Phoenix Children's Hospital
Author Profile
Alok Kothari
Phoenix Children's Hospital
Author Profile

Abstract

Genetically-targeted medications are emerging as important therapies for lymphatic malformations (LMs) unresponsive to sirolimus. We describe two patients with EML4::ALK positive LMs, one with Gorham Stout Disease and one with a large genitourinary (GU) LM, who were successfully treated with ALK inhibitors. This report adds ALK inhibitors to the growing toolbox of molecularly-targeted therapies for LMs.
31 Jul 2024Submission Checks Completed
31 Jul 2024Assigned to Editor
31 Jul 2024Submitted to Pediatric Blood & Cancer
02 Aug 2024Review(s) Completed, Editorial Evaluation Pending
07 Aug 2024Reviewer(s) Assigned
23 Sep 2024Editorial Decision: Revise Minor
08 Oct 2024Submission Checks Completed
08 Oct 2024Assigned to Editor
08 Oct 20241st Revision Received
08 Oct 2024Review(s) Completed, Editorial Evaluation Pending
08 Oct 2024Reviewer(s) Assigned
27 Oct 2024Editorial Decision: Accept